Ibuprofen and Paracetamol: Acceptably Safe for All? Filippo PigazzaniIsla MackenzieThomas M. MacDonald Commentary Open access 22 August 2018 Pages: 999 - 1001
What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects Rike van EekerenLeàn RolfesLinda Härmark Current Opinion Open access 13 June 2018 Pages: 1003 - 1011
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction Ylenia IngrasciottaPaola M. CutroneoGianluca Trifirò Leading Article 23 May 2018 Pages: 1013 - 1022
Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit Adeleke D. AdewumiChristine E. StaatzRosa Alati Review Article 23 May 2018 Pages: 1023 - 1033
Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis Clara Crespillo-AndújarEmmanuele Venanzi-RulloJosé A. Pérez-Molina Systematic Review 13 July 2018 Pages: 1035 - 1048
Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample Mai DuongAbdelilah AbouelfathNicholas Moore Original Research Article 24 May 2018 Pages: 1049 - 1058
Predicting Adverse Drug Effects from Literature- and Database-Mined Assertions Mary K. LaAlexander SedykhAlexander Tropsha Original Research Article 06 June 2018 Pages: 1059 - 1072
MOdified NARanjo Causality Scale for ICSRs (MONARCSi): A Decision Support Tool for Safety Scientists Shaun ComfortDarren DorrellJennifer Fine Original Research Article Open access 06 June 2018 Pages: 1073 - 1085
Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological–Pharmacodynamic Study in VigiBase® Thi Thu Ha NguyenAnne RoussinFrançois Montastruc Original Research Article 28 June 2018 Pages: 1087 - 1096
Comment on “Using Human ‘Experiments of Nature’ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors” Lucas D. WardGraeme J. MoffatPaul Nioi Letter to the Editor Open access 31 July 2018 Pages: 1097 - 1099
Reply to Ward and Colleagues’ Comment on “Using Human Experiments of Nature to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors” Rebecca N. JeromeJill M. PulleyJoshua C. Denny Letter to the Editor 31 July 2018 Pages: 1101 - 1101
18th ISoP Annual Meeting “Pharmacovigilance without borders” Geneva, Switzerland, 11–14 November, 2018 Abstracts 03 October 2018 Pages: 1103 - 1273